Shenzhen Hepalink, the world's largest maker of the blood-thinner heparin, recently launched its US$868m IPO, becoming the record holder of the highest IPO share price in China’s A-share market. Zhong Lun partners Su Min, Xu Zhigang and Zou Xiaodong facilitated the listing. The firm has been long-term legal advisor to the issuer since a decade ago.

Hepalink was founded in 1998 and primarily produces herapin, which is purified from pig intestines then made into a shot used to prevent blood clots in patients with heart conditions. The company is the only Chinese company accredited by the US Food and Drug Administration to export herapin.

Zhejiang Narada Power Source, which principally engages in the research, development, manufacturing and sale of chemical power sources and new energy products, is another another company to have sought to raise funds from listing on the Shenzhen board. Advised by AllBright partner Zhang Xiaohong, the firm’s debut raised about US$287m.

According to Dealogic, since January 2010 there have been nine IPOs in Shanghai raising some US$7.7bn and 59 in Shenzhen raising US$7.3bn.

Related stories:

• Guantao facilitates Financial Street bonds
• Shenzhen GEM could be jewel in capital markets crown
• Grandall leads in Chinese SME IPOs